InvestorPlace

Ignore the Naysayers and Invest in Novavax Stock

Novavax (NASDAQ:NVAX) has been on a roll of late. Its Covid-19 vaccine got green-lit in Indonesia, which is likely to open the floodgates for approvals in other countries. Its coronavirus vaccine is more effective than the competition’s and already has orders of close to 2 billion doses. Moreover, Novavax isn’t a one-trick pony like Moderna (NASDAQ:MRNA), as it boasts an incredible product pipeline, with multiple vaccines in advanced trials. In short, NVAX stock remains a strong-yet-undervalued